article thumbnail

Jupiter Neurosciences Makes Way in CNS Treatments with $11M IPO

XTalks

Jotrol overcomes these barriers using patented micellar technology, enhancing bioavailability and enabling therapeutically effective doses. Proceeds from the IPO will propel key initiatives, including the Phase II clinical trial of Jotrol in Parkinson’s disease.

article thumbnail

Novaliq’s dry eye disease therapy receives US FDA approval

Pharmaceutical Technology

The water-free formulation of the investigational drug increases residual time on the surface of the eye and improves bioavailability in the target tissues to release the complete potential of cyclosporine A.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

CellCentric Strengthens Leadership Team

Pharma Mirror

CellCentric is developing inobrodib, an orally bioavailable drug that is transitioning into Phase II clinical trials in multiple indications. Both have stellar experience and track records in oncology research and development.

article thumbnail

BeiGene’s Brukinsa receives UK marketing authorisations to treat cancers

Pharmaceutical Technology

Brukinsa is a small-molecule Bruton’s tyrosine kinase (BTK) inhibitor specially designed for delivering sustained and targeted BTK protein inhibition by optimising bioavailability, half-life, and selectivity. The regulatory approval for the BTK inhibitor to treat CLL was based on Phase III SEQUOIA and ALPINE clinical trials.

Marketing 130
article thumbnail

Obesity-Focused Metsera Launches IPO Amid Much Anticipation

XTalks

XTALKS WEBINAR: GLP-1 Agonist Development: Endpoint Strategies to Help Differentiate Your Drug Live and On-Demand: Tuesday, February 25, 2025, at 11am EST (4pm GMT/UK) Register for this free webinar to learn how innovative digital and imaging endpoints can maximize the value of GLP-1 clinical trials. in its Phase Ib trial.

article thumbnail

Orphagen’s ACC therapy receives FDA rare pediatric disease status

Pharmaceutical Technology

OR-449 is a first-in-class, orally bioavailable, potent and selective small molecule antagonist of the orphan nuclear receptor steroidogenic factor-1 (SF-1, NR5A1). We currently plan to file an Investigational New Drug (IND) application with the FDA later this year to support the initiation of a Phase I clinical trial. “We

article thumbnail

Erasca receives fast track designation for glioblastoma therapy

Pharmaceutical Technology

The orally bioavailable small molecule EGFR inhibitor ERAS-801 demonstrated significant central nervous system (CNS) penetration in animal trials. This newly granted status helps Erasca to facilitate the development and review of ERAS-801, thereby accelerating the therapy’s reach to patients. “To